Emergent BioSolutions Inc. (EBS): Cash & Equivalents
$205.40M
As of 2025-12-31
$139.70M
As of 2026-06-30
-31.6%
3-year compound annual growth
-19.9%
5-year compound annual growth
-4.1%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $205.40M | +106.4% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $99.50M | -10.9% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $111.70M | -82.6% | 2026-02-27, Balance as of period end |
| 2022-12-31 | $642.60M | +11.5% | 2025-03-04, Balance as of period end |
| 2021-12-31 | $576.10M | -7.3% | 2023-12-11, Balance as of period end |
| 2020-12-31 | $621.30M | +270.3% | 2023-12-11, Balance as of period end |
| 2019-12-31 | $167.80M | +49.6% | 2022-02-25, Balance as of period end |
| 2018-12-31 | $112.20M | -37.1% | 2021-02-19, Balance as of period end |
| 2017-12-31 | $178.30M | -34.3% | 2020-02-25, Balance as of period end |
| 2016-12-31 | $271.50M | -13.2% | 2019-02-22, Balance as of period end |
| 2015-12-31 | $312.80M | +11.5% | 2018-02-23, Balance as of period end |
| 2014-12-31 | $280.50M | +56.4% | 2017-02-28, Balance as of period end |
| 2013-12-31 | $179.34M | +26.6% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $141.67M | -1.6% | 2015-03-09, Balance as of period end |
| 2011-12-31 | $143.90M | -14.9% | 2014-03-10, Balance as of period end |
| 2010-12-31 | $169.02M | +64.2% | 2013-03-08, Balance as of period end |
| 2009-12-31 | $102.92M | n/a | 2012-03-09, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $205.40M | +106.4% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $158.54M | -42.7% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $120.50M | -5.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $170.18M | +12.2% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $128.45M | +85.3% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $231.25M | +227.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $421.00M | +142.0% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $322.93M | +2.4% |
Compare EBS, PCRX, CORT, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗